Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HIV vaccines polytope - Bavarian Nordic/VaxOnco

Drug Profile

HIV vaccines polytope - Bavarian Nordic/VaxOnco

Alternative Names: EP 1232; EP 1233; EP-1232 + EP-1233; HIV DNA vaccine + MVA HIV vaccine - Bavarian Nordic; MVA-BN Polytope; MVA-BN32; MVA-mBN32

Latest Information Update: 20 Apr 2012

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bavarian Nordic; Pharmexa-Epimmune
  • Developer Bavarian Nordic; VaxOnco
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued HIV-1 infections

Most Recent Events

  • 20 Apr 2012 Discontinued - Phase-I for HIV-1 infections in Germany (Parenteral)
  • 20 Apr 2012 Discontinued - Phase-I for HIV-1 infections in USA (Parenteral)
  • 20 Apr 2012 Discontinued - Phase-I/II for HIV-1 infections in Germany (Parenteral)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top